Phio Pharmaceuticals Corp. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Phio Pharmaceuticals (market cap ~$11.2M) completed its Phase 1b clinical trial for PH-762, an siRNA therapeutic targeting PD-1 in cutaneous squamous cell carcinoma, and submitted a comprehensive briefing package to the FDA requesting a Type B meeting to discuss the planned Phase 2b neoadjuvant study. Clinical supplies for Phase 2b are expected in Q1 2027, with nonclinical toxicology dosing completed; final regulatory support activities targeted for Q1 2027.
Why this rating
Clinical-stage biotech; Phase 1b completion and FDA engagement is material progression. No financial terms disclosed. At $11.2M valuation, successful Phase 2b advancement could substantially improve prospects and de-risk pipeline.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.05 ▼ 0.07% | at our read · unknown $1.05 | +10 min · unknown $1.05 ▼ 0.10% | +30 min · unknown $1.03 ▼ 1.33% | +1 hr · unknown $1.01 ▼ 3.24% | +4 hrs pending |
The stock had already moved +0.07% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.